HTA and health economics

HTA and budget impact analysis for medical devices

Health technology assessment is the language in which value is discussed with payers. We prepare systematic literature reviews, health-economic models, budget impact analyses for Czechia and MER for Slovakia — and translate them into an argument that survives the procedure.

HTA and health economicsBIA for CZ, MER for SKSystematic literature reviews

Why it works

Pharma methodology applied to med-tech

HTA for medicinal products has settled methodology. For devices the situation differs: the evidence base is smaller, the comparator is often unclear, and part of the value sits outside clinical benefit — in care organisation, length of stay or downstream resource use.

Our advantage is that we do both, and adapt the discipline of pharma HTA to how devices are actually assessed.

A note on EU HTA

Joint European assessment reaches medical devices gradually and does not replace national reimbursement procedures. We prepare data so it can serve both.

  • Systematic literature reviews and evidence appraisal
  • Health-economic modelling and cost-effectiveness
  • Budget impact analysis for Czechia
  • Pharmacoeconomic analysis and MER for Slovakia
  • Real-world data and registry analyses
  • Medical society and KOL engagement

FAQ

Questions we hear most

Answers reflect the rules and decision practice as of September 2026.

Our clinical evidence is thin. Is HTA still worth it?

Often especially then. Limited evidence does not prevent an argument; it means uncertainty has to be handled honestly. A sensitivity analysis showing the result holds under conservative assumptions is stronger than an optimistic single scenario.

The review usually also reveals which data are missing — a useful input for a PMCF plan or real-world data collection.

How does BIA differ from cost-effectiveness analysis?

A budget impact analysis answers what the technology will cost the payer over a defined horizon, using real population and uptake. A cost-effectiveness analysis answers whether the benefit justifies the cost, typically per patient.

For Czech device reimbursement, BIA is in practice the more decisive of the two.

Need a model that defends the value of your device?

Tell us about the technology and who you need to convince. We will scope the analysis to the data you actually have.

Managing DirectorMartin Kolekmartin.kolek@ceeor.com+420 728 411 042
Regulatory AffairsIvana Kubátováivana.kubatova@ceeor.com+420 602 345 190